-
HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody
2026-08-22
Translate rabbit-primary immunodetection into clear red-channel readouts across ICC/IF, tissue staining, flow cytometry, and ELISA. This workflow guide shows how to use HyperFluor™ 594 for neuroblastoma nanomedicine studies, multiplex assays, and troubleshooting-sensitive validation experiments.
-
Dabigatran for Thromboembolic Disorders: Evidence Review
2026-08-21
The 2015 review positions dabigatran as the first widely introduced non-vitamin K oral anticoagulant and integrates pharmacology with evidence from atrial fibrillation, orthopedic thromboprophylaxis, and acute venous thromboembolism. Its practical contribution is showing how predictable anticoagulation and reduced intracranial bleeding must be balanced against renal clearance, drug interactions, and bleeding-management challenges.
-
rhBNP, Selenium Recycling, and Renal Ferroptosis
2026-08-20
This study identifies selenocysteine lyase 1 (SCLY)-dependent selenium recycling as a mechanistic basis for the renal protection conferred by recombinant human brain natriuretic peptide (rhBNP) during ischemia-reperfusion injury. By integrating clinical observations, rat models, transcriptomics, and HK2-cell perturbation experiments, the work connects rhBNP signaling with suppression of ferroptosis and provides a testable target for acute kidney injury research.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-20
A 2025 study found that naturally occurring angiotensin fragments can increase SARS-CoV-2 spike-protein binding to host receptors, with particularly strong effects observed for shorter peptides and angiotensin IV. The work connects renin–angiotensin system biology with viral receptor recognition and provides a comparative framework for testing peptide structure, receptor selectivity, and translational relevance.
-
Nullscript: HDAC Inhibition as an Assay Strategy
2026-08-19
Nullscript is a histone deacetylase inhibitor with an unusual separation between HDAC inhibition and transcriptional facilitation. This article explains how that profile can sharpen cardiac ischemia/reperfusion assays and help researchers interpret epigenetic contributions to injury biology without confusing correlation with mechanism.
-
Toremifene vs Tamoxifen in Advanced Breast Cancer
2026-08-19
This Cochrane review directly compared toremifene and tamoxifen for advanced breast cancer, focusing on tumor response, progression, survival, and treatment-related adverse events. Its main practical implication is that available randomized evidence did not demonstrate a consistent efficacy or safety advantage for either endocrine agent, while limitations in trial reporting constrain claims of equivalence.
-
Dynasore Workflows for Endocytosis Research
2026-08-18
Dynasore is a reversible dynamin GTPase inhibitor for separating membrane-fission events from downstream trafficking and signaling. This practical guide translates pharmacology, cargo-uptake assays, and the GCRV entry study into optimized workflows for endocytosis research, neuronal models, and carefully controlled pathway experiments.
-
FITC Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-08-18
This reagent provides fluorescein-based detection of mouse IgG primary antibodies in immunofluorescence, fluorescence microscopy, and flow cytometry workflows. It should not be assumed suitable for non-mouse primary antibodies, live-cell assays, or unvalidated assay formats without compatibility testing.
-
Latrunculin B for Transient Actin Studies
2026-08-17
Latrunculin B provides reversible, short-duration control of actin filament assembly for live-cell imaging, cytoskeletal organization studies, and entry-pathway experiments. Its value is greatest when exposure time, serum effects, and orthogonal controls are designed into the workflow rather than treated as afterthoughts.
-
Bradykinin (BA5201): Practical Research Workflow
2026-08-17
Bradykinin (BA5201) provides a defined research peptide for acute studies of endothelium-dependent vasodilation, vascular permeability, smooth muscle contraction, pain mechanisms, and inflammation signaling. It is intended for controlled scientific experiments only; it should not be used for diagnosis, treatment, or direct clinical blood pressure management.
-
FGF4-FGFR1 Signaling Protects Podocytes in DKD
2026-08-16
This Nature Communications study identifies podocyte-secreted FGF4 as an endogenous regulator of glomerular integrity in diabetic kidney disease. Genetic loss-of-function, recombinant FGF4 treatment, and human podocyte experiments converge on an FGFR1–AMPK–FOXO1 pathway that limits oxidative stress and apoptosis, providing a mechanistic basis for protecting podocyte survival.
-
Latrunculin B: Actin Control for Translational Insight
2026-08-15
Latrunculin B is more than a cytoskeletal perturbagen: its reversible control of G-actin provides a rigorous way to test pathway dependence, define assay windows, and interpret negative results in translational cell biology and antiviral research.
-
CX-4945: CK2 Target Engagement Beyond Cancer
2026-08-14
CX-4945 (Silmitasertib) is a selective ATP-competitive CK2 inhibitor for connecting kinase target engagement with cancer and host-pathogen biology. This article develops a causal assay framework based on CK2α-dependent viral replication, rather than repeating a conventional inhibitor protocol.
-
Ciprofloxacin Hydrochloride Assay Workflows
2026-08-14
Build more informative antibacterial assays with Ciprofloxacin hydrochloride, from MIC and combination matrices to single-cell survival and SOS-response measurements. This workflow-focused guide also separates DNA-damage biology from host immunomodulatory readouts, helping researchers avoid misleading endpoint comparisons.
-
DNA Removal as a Translational Quality Variable
2026-08-13
A mechanistic and strategic guide to using DNase I (RNase-free) for RNA integrity, assay confidence, and translational reproducibility.